SGLT2 inhibition: Efficacy and safety in type 2 diabetes treatment

Expert Opinion on Drug Safety

Volumn 14, Issue 12, 2015, Pages 1879-1904

  Scheen, André J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Department of Medicine   (Belgium)

Author keywords

canagliflozin; dapagliflozin; empagliflozin; oral antidiabetic drug; SGLT2 inhibitor; type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PLACEBO; POTASSIUM; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; URIC ACID; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

BLADDER CANCER; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY WEIGHT; BONE METABOLISM; BREAST CANCER; CALORIC INTAKE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONTROL; DEHYDRATION; DIET; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FRACTURE; FRAIL ELDERLY; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; INFECTION RISK; INSULIN TREATMENT; KETOACIDOSIS; KIDNEY FAILURE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PANCREAS ISLET BETA CELL; PATIENT CARE; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT CHANGE; WEIGHT REDUCTION; AGED; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM; PATHOPHYSIOLOGY;

AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84951905769     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1100167     Document Type: Review

References (131)

1. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1:140-151
2. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297-322
3. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63-71
4. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515-531
5. Scheen AJ. Drug-drug interactions with SGLT-2 inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes. Clin Pharmacokinet. 2014;53:295-304
6. Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Clin Pharmacokinet. 2015;54:691-708
7. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-Analysis. Ann Intern Med. 2013;159:262-274
8. Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: A meta-Analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013;13:58
9. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33-59
10. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149
11. Plosker GL. Canagliflozin: A review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:807-824
12. European Medicines Agency [Internet]. Assessment report. Canagliflozin. 2013. [cited 2015 Oct 15]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-Assessment-report/human/002649/WC500156457.pdf
13. Plosker GL. Dapagliflozin: A review of its use in type 2 diabetes mellitus. Drugs. 2012;72:2289-2312
14. Plosker GL. Dapagliflozin: A review of its use in patients with type 2 diabetes. Drugs. 2014;74:2191-2209
15. European Medicines Agency [Internet]. Assessment report. Forxiga (dapagliflozin). 2012. [cited 2015 Oct 15]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-Assessment-report/human/002322/WC500136024.pdf
16. Scott LJ. Empagliflozin: A review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:1769-1784
17. European Medicines Agency. Assessment report: Jardiance [Internet]. International non-proprietary name: empagliflozin. 2014. [cited 2015 Oct 15]. Available from: http://www.ema.europa.eu/docs/en-GB/docu ment-library/EPAR-Public-Assessment-report/human/002677/WC500168594.pdf.
18. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015. Epub 2015 Sep 17. DOI:10.1056/NEJMoa1504720
19. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-1380
20. Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306:F188-93
21. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154-2161
22. Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015;17:188-197
23. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014;57:891-901
24. Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs. 2013;73:979-988
25. Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013;9:763-775
26. Yang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-Analysis. Eur J Clin Pharmacol. 2014;70:1149-1158
27. Bode B, Stenlof K, Harris S, et al. Longterm efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294-303
28. Rosenstock J, Chuck L, Gonzlez-Ortiz M, et al. Initial combination therapy with canagliflozin (CANA) plus metformin extended-release (MET XR) in drug-nave type 2 diabetes mellitus (T2DM). Abstract presented at the annual meeting of the American Diabetes Association; 2015 June; Boston. LB DIA3011 abstract 2015
29. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941-950
30. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia. 2013;56:2582-2592
31. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial. Diabetes Care. 2013;36:2508-2515
32. Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355-364
33. Bailey RA, Damaraju CV, Martin SC, et al. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. Am J Manag Care. 2014;20: S16-24
34. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab. 2015;100:1927-1932
35. Scheen AJ, Paquot N. Metabolic effects SGLT2 inhibitors beyond increased glucosuria: A review of clinical evidence. Diabetes Metab. 2014;40:S4-S11
36. Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53:17-27
37. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43
38. Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159-169
39. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124-136
40. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose cotransport (SGLT) inhibitors: systematic review and meta-Analysis of randomized trials. Ann Med. 2012;44:375-393
41. Sun YN, Zhou Y, Chen X, et al. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-Analysis of randomised controlled trials. BMJ Open. 2014 4:e004619. doi:10.1136/bmjopen-2013-004619
42. Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: A systematic review and meta-Analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30:204-221
43. List JF, Woo V, Morales E, et al. Sodiumglucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657
44. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446-456
45. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015-2022
46. Nauck MA, Del Prato S, Duran-Garcia S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16:1111-1120
47. Del Prato S, Nauck M, Duran-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17:581-590
48. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376-383
49. Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: A systematic review and network meta-Analysis. Diabetes Obes Metab. 2014;16:433-442
50. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213-225
51. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:152-161
52. Merker L, Haring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet Med. 2015. doi:10.1111/dme.12814
53. Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37:1773-1788
54. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebocontrolled trial. Diabetes Obes Metab. 2015;17:936-948
55. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and meta-Analysis. Diabetes Obes Metab. 2014;16:984-993
56. Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:721-728
57. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015-4021
58. Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, doubleblind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691-700
59. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154-1160
60. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy in drug-nave patients with type 2 diabetes: A randomised, 24-week, double-blind, placebocontrolled, parallel group, trial with sitagliptin as active comparator. Lancet Diabetes Endocrinol. 2013;1:208-219
61. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394-402
62. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384-393
63. Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med. 2013;125:92-100
64. Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:911-922
65. Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161-1172
66. Cefalu WT, Stenlof K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183-1187
67. Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126:7-15
68. Lambers Heerspink HJ, De Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853-862
69. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020-1031
70. Sjostrom CD, Hashemi M, Sugg J, et al. Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels. Diabetes Obes Metab. 2015;17:809-812
71. Grandy S, Hashemi M, Langkilde AM, et al. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab. 2014;16:645-650
72. Neeland I, McGuire DK, Chilton RJ, et al. The sodium glucose co-transporter 2 inhibitor (SGLT2i) empagliflozin reduces weight and markers of visceral adiposity (VA) in type 2 diabetes (T2D) in short-And intermediate term [abstract]. Circulation. 2014;130: 16518
73. Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium glucose cotransporter 2 (SGLT2) inhibition. Diabetes Care. 2015;38:1730-1735
74. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480-1483
75. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330-339
76. Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens. 2015;9:48-53
77. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-Analysis. J Am Soc Hypertens. 2014;8:262-75 e9
78. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:1087-1095
79. Sjostrom CD, Johansson P, Ptaszynska A, et al. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12:352-358
80. Engeli S, Jordan J. Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients? Curr Hypertens Rep. 2013;15:470-474
81. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420-428
82. Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologicallyinduced glucosuria. Diabetes Res Clin Pract. 2014;103:373-381
83. Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012;28:1167-1171
84. Mikhail N. Safety of canagliflozin in patients with type 2 diabetes. Curr Drug Saf. 2014;9:127-132
85. Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473-478
86. Ptaszynska A, Johnsson KM, Parikh SJ, et al. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014;37:815-829
87. Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28:1173-1178
88. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: A pooled analysis of clinical studies. Curr Med Res Opin. 2014;30:1109-1119
89. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:479-484
90. Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30:1759-1768
91. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351-375
92. De Nicola L, Gabbai FB, Liberti ME, et al. Sodium/Glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64:16-24
93. US Food and Drug Administration. Drug safety communications: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet]. 2015. [cited 2015 Oct 15]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf
94. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687-1693
95. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514
96. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508
97. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-517
98. Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849-2852
99. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38: 1680-1686
100. Ptaszynska A, Hardy E, Johnsson E, et al. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med. 2013;125:181-189
101. Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391-404
102. Davies MJ, Trujillo A, Vijapurkar U, et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:426-429
103. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8-10
104. Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990-999
105. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962-971
106. Lin HW, Tseng CH. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. 2014;2014:719578
107. Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Hosp Pract (1995).2013;41:72-84
108. Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: A pooled analysis of clinical studies. BMC Endocr Disord. 2014;14:37
109. Leiter LA, Cefalu WT, De Bruin TW, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62:1252-1262
110. Elmore LK, Baggett S, Kyle JA, et al. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes. Consult Pharm. 2014;29:335-346
111. Mikhail N. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South Med J. 2015;108:91-96
112. Scheen AJ. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2014;10:647-663
113. Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76:432-444
114. Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16:215-222
115. Devineni D, Marbury T, Curtin C, et al. Effects of renal function on canagliflozin (CANA) pharmacokinetics (PK) and pharmacodynamics (PD) in non-diabetic subjects. JASN Abstract Supplement of the American Society of Nephrology (ASN) Kidney Week; 2012 October 30-November 4; San Diego (CA); 2012. Abstract# PUB295
116. Food and Drug Administration. Center for drug evaluation and research report [Internet]. Canagliflozin (Invokana). 2013. [cited 2015 Oct 15]. Available from: http://www.accessdata.fda.gov/drug satfda-docs/nda/2013/204042Orig1s000ClinPharmR.pdf
117. Ferrannini E, Veltkamp SA, Smulders RA, et al. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2013;36:1260-1265
118. Yamout H, Perkovic V, Davies M, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40:64-74
119. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463-473
120. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016-1027
121. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, doubleblind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369-384
122. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol. 2013;9:529-550
123. Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications. 2013;27:280-286
124. Cefalu WT, Leiter LA, De Bruin TW, et al. Dapagliflozins effects on glycemia and cardiovascular risk factors in highrisk patients with type 2 diabetes: A 24-week, multicenter, randomized, doubleblind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38:1218-1227
125. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res. 2012;9:117-123
126. Neal B, Perkovic V, De Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) : A randomized placebo-controlled trial. Am Heart J. 2013;166:217-23 e11
127. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014;13:102
128. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38:412-419
129. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: A 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17:928-935
130. Scheen AJ. SGLT2 versus DPP4 inhibitors for type 2 diabetes. Lancet Diabetes Endocrinol. 2013;1:168-170
131. Bell DS. The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss. Am J Case Rep. 2014;15:152-154.